NCT06461819View on ClinicalTrials.gov

Safety of Dose Escalation in Definitive Hypofractionated Radiation Therapy With SPACEOAR TM for Patients With Low-to-intermediate Risk Localized Prostate Cancer (DESAR-L)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 11, 2023

Primary Completion Date

December 31, 2033

Study Completion Date

December 31, 2033

Conditions

Low-to-intermediate-risk Prostate Carcinoma

Interventions

RADIATION

Low- and medium-risk studies performed after biodegradable substance injection prostate cancer dose increase.

this researcher used a biodegradable material injection technique. after subdivision radical received radiation therapy We plan to conduct a phase II clinical study to evaluate the safety of prostate cancer patients.

Trial Locations (1)

06351

RECRUITING

Samsung Medical Center, Seoul

All Listed Sponsors

lead

Samsung Medical Center

OTHER